Shares of Clover Health Investments, Corp. (NASDAQ:CLOV - Get Free Report) dropped 8.8% during trading on Wednesday. The company traded as low as $4.37 and last traded at $4.3150. Approximately 2,214,418 shares were traded during trading, a decline of 62% from the average daily volume of 5,781,903 shares. The stock had previously closed at $4.73.
Analysts Set New Price Targets
CLOV has been the topic of a number of recent research reports. Canaccord Genuity Group upped their target price on shares of Clover Health Investments from $4.20 to $5.50 and gave the stock a "buy" rating in a research report on Tuesday, July 21st. Zacks Research raised shares of Clover Health Investments to a "hold" rating in a research report on Monday, September 14th. UBS Group boosted their price objective on shares of Clover Health Investments from $5.00 to $5.50 and gave the stock a "neutral" rating in a research note on Thursday, November 5th. Needham & Company LLC restated a "buy" rating on shares of Clover Health Investments in a report on Thursday, November 5th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Clover Health Investments in a research note on Monday, September 21st. Three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $5.10.
Check Out Our Latest Analysis on CLOV
Clover Health Investments Stock Performance
The stock has a market cap of $2.34 billion, a PE ratio of 438.94 and a beta of 2.52. The firm has a 50-day moving average price of $4.63 and a 200-day moving average price of $3.67.
Clover Health Investments (NASDAQ:CLOV - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.02. Clover Health Investments had a net margin of 0.45% and a return on equity of 4.66%. The company had revenue of $759.30 million for the quarter, compared to the consensus estimate of $740.07 million. As a group, sell-side analysts anticipate that Clover Health Investments, Corp. will post 0.06 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, CEO Conrad Wai sold 23,627 shares of Clover Health Investments stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $4.68, for a total value of $110,574.36. Following the completion of the sale, the chief executive officer directly owned 1,042,072 shares in the company, valued at approximately $4,876,896.96. This trade represents a 2.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, VP Joseph Frank Oldakowski sold 20,000 shares of the business's stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $5.16, for a total value of $103,200.00. Following the completion of the transaction, the vice president directly owned 279,067 shares of the company's stock, valued at approximately $1,439,985.72. This trade represents a 6.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 768,573 shares of company stock valued at $3,462,479. 23.51% of the stock is currently owned by corporate insiders.
Institutional Trading of Clover Health Investments
A number of hedge funds and other institutional investors have recently bought and sold shares of CLOV. Goldman Sachs Group Inc. lifted its position in Clover Health Investments by 40.4% in the third quarter. Goldman Sachs Group Inc. now owns 1,643,899 shares of the company's stock worth $7,085,000 after buying an additional 473,157 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Clover Health Investments in the second quarter valued at $6,346,000. California State Teachers Retirement System boosted its stake in shares of Clover Health Investments by 24.1% during the 1st quarter. California State Teachers Retirement System now owns 497,006 shares of the company's stock worth $875,000 after purchasing an additional 96,458 shares during the period. Tidal Investments LLC purchased a new position in shares of Clover Health Investments during the 2nd quarter worth about $2,156,000. Finally, Algert Global LLC boosted its stake in shares of Clover Health Investments by 6.2% during the 3rd quarter. Algert Global LLC now owns 398,440 shares of the company's stock worth $1,717,000 after purchasing an additional 23,360 shares during the period. Hedge funds and other institutional investors own 19.77% of the company's stock.
About Clover Health Investments
(
Get Free Report)
Clover Health Investments is a U.S. healthcare company focused on Medicare. Its insurance business offers Medicare Advantage plans to eligible beneficiaries in select markets, combining medical coverage with support intended to help members access care. The company also developed the Clover Assistant, a technology platform that organizes patient information and provides clinicians with insights to support care decisions. Clover has described the platform as a way to help primary care providers identify health needs and coordinate care for people with complex conditions.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Clover Health Investments, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clover Health Investments wasn't on the list.
While Clover Health Investments currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.